Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -4.17
- Piotroski Score 2.00
- Grade Market Perform
- Symbol (NGM)
- Company NGM Biopharmaceuticals, Inc.
- Price $1.54
- Changes Percentage (-1.28%)
- Change -$0.02
- Day Low $1.54
- Day High $1.57
- Year High $4.69
NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company's product candidates include Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trials for the treatment of non-alcoholic steatohepatitis (NASH); and MK-3655, an agonistic antibody that activates fibroblast growth factor receptor 1c-beta-klotho, which is in Phase IIb clinical trials for use in the treatment of type 2 diabetes and NASH. Its products under development also comprise NGM120, an antagonist antibody that binds GFRAL that is in Phase I/II clinical trials; NGM621, an immunoglobulin 1 monoclonal antibody in Phase II clinical trials for the treatment of geographic atrophy; NGM707, an immunoglobulin-like transcript 2/ immunoglobulin-like transcript 4 dual antagonist monoclonal antibody that is in Phase I/II clinical trials for the treatment of patients with advanced solid tumors; and NGM831 and NGM438 for the treatment of advanced solid tumors. The company has research collaboration, product development, and license agreements with Merck Sharp & Dohme Corp.; and a collaboration agreement with Merck & Co., Inc. to focus primarily on the development of novel medicines for unmet patient needs in retinal and CVM diseases, including heart failure. NGM Biopharmaceuticals, Inc. was incorporated in 2007 and is headquartered in South San Francisco, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 05/01/2024
- Fiscal Year End N/A
- Average Stock Price Target $16.50
- High Stock Price Target $29.00
- Low Stock Price Target $4.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$1.73
- Trailing P/E Ratio -0.89017341040462
- Forward P/E Ratio -0.89017341040462
- P/E Growth -0.89017341040462
- Net Income $-142,375,000
Income Statement
Quarterly
Annual
Latest News of NGM
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Meet Peter Thiel, the controversial tech billionaire and GOP kingmaker
Peter Thiel's net worth soared to $14 billion after Trump's reelection. A key figure in Vance's rise, Thiel backed him financially and strategically, solidifying his role as a conservative kingmaker....
By Business Insider | 1 week ago -
Global strongmen eye closer US ties from Trump win
Donald Trump's presidency return may shift U.S. foreign policy towards aligning with populist and authoritarian leaders globally. Trump's second term could prioritize transactional alliances over demo...
By Newsweek | 2 weeks ago -
The Man Who Shaped China's Strongman Rule Has a New Job: Winning Taiwan
Wang Huning, a key ideological adviser to China's leader Xi Jinping, has risen to power through his influence on party doctrines and policies. His role in shaping China's direction, especially in hand...
By The New York Times | 3 weeks ago
